Novartis' Sandoz division has filed its biosimilar of Humira in the US, aiming to take a share of its multi-billion dollar revenues once its patent expires. The generics and biosimilars arm of ...
Crucially, Humira costs the NHS more than £500 million a year, a sum that NHS England wants to see fall through biosimilar use. Sandoz is one such company that hopes to offer the NHS savings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback